Amplia Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INNMF research report →
About the company
Established in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics Limited is a pharmaceutical firm dedicated to the discovery and development of focal adhesion kinase (FAK) inhibitors. The company's therapeutic endeavors are concentrated on oncology (cancer) and chronic fibrotic diseases. Its drug development pipeline includes AMP945, a FAK inhibitor that has successfully completed Phase I clinical trials and is being explored for its efficacy in treating pancreatic cancer, idiopathic pulmonary fibrosis, and a broader spectrum of cancerous and fibrotic conditions.
- CEO
- Christopher J. Burns
- IPO
- 2021
- Employees
- 1
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $59.03M
- P/E
- -8.98
- P/S
- 0.00
- P/B
- 1.95
- EV/EBITDA
- -3.84
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -18.71%
- ROIC
- -20.41%
- Revenue
- $0 · -100.00%
- Net Income
- $-7,721,716 · -17.49%
- EPS
- $-0.02 · 23.36%
- Op Income
- $-13,205,020
- FCF YoY
- -27.52%
- 52W High
- $0.27
- 52W Low
- $0.05
- 50D MA
- $0.10
- 200D MA
- $0.10
- Beta
- -0.39
- Avg Volume
- 31.23K
Get TickerSpark's AI analysis on INNMF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our INNMF coverage
Recent articles, reports, and earnings notes.
No research on INNMF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INNMF report →Similar companies
Peers in the same neighborhood.